周六报道，Alnylam Pharmaceuticals HEIOS-B AMVUTTRA三期研究显示，Vutrisiran改善了淀粉样蛋白消退和肾功能保留的ATTR-CM患者的心脏结构和功能

2025-11-10 16:58

− Analyses Presented at the American Heart Association Scientific Sessions 2025 Underscore Vutrisiran's Differentiated Profile –
− Cardiovascular Magnetic Resonance (CMR) and Echocardiographic Analyses Demonstrate that Treatment with Vutrisiran Resulted in Significant Changes on Multiple Functional and Structural Cardiac Parameters –
– In a Cohort of HELIOS-B Patients, CMR Imaging Showed Amyloid Regression in 22% of Vutrisiran Treated Patients with No Regression Found in Patients Who Received Placebo –
– Treatment with Vutrisiran Preserved Kidney Function in HELIOS-B Patients, and Reduced Risk of Death and Cardiovascular Events in Patients with Advanced Chronic Kidney Disease –